Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: Am J Cardiol. 2024 Jan 7;214:59–65. doi: 10.1016/j.amjcard.2023.12.052

Figure 1.

Figure 1.

Cumulative incidence of adverse events in patients with and without CTO. Unadjusted cumulative incidence function was used to visualize differences in survival outcomes in patients with CTO (n = 922) and significant CAD without CTO (n = 2,675), coupled with log-rank tests. CTO was associated with higher event rates of all-cause mortality, cardiovascular death, and a MACE, defined as a composite of cardiovascular death/MI/HF hospitalization. The no-CTO group had significant CAD, defined as ≥50% stenosis in ≥1 coronary artery.